Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Adaptive Biotechnologies (Nasdaq: ADPT) announced participation in two upcoming investor conferences. The company will host 1x1 meetings at the Craig-Hallum 23rd Annual Institutional Investor Conference on May 28 in Minneapolis and present at the William Blair 46th Annual Growth Stock Conference on June 3 at 3:20 p.m. Central Time.

A live and archived webcast of the William Blair presentation will be available in the Investors section of the company website.

News Market Reaction – ADPT

+0.07%

1 alert

+0.07% Session close to close

$2.14B Market Cap

0.0x Rel. Volume

In the May 22 session, ADPT gained 0.07%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences.

• Craig-Hallum 23^rd Annual Institutional Investor Conference – Minneapolis, MN
  Hosting 1x1 meetings on Thursday, May 28^th
• William Blair 46^th Annual Growth Stock Conference – Chicago, IL
  Presentation on Wednesday, June 3^rd at 3:20 p.m. Central Time
  
  

Interested parties may access a live and archived webcast of the presentation from the William Blair Growth Stock Conference on the “Investors” section of the company website at: www.adaptivebiotech.com.

About Adaptive Biotechnologies

Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com

ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
media@adaptivebiotech.com

FAQ

When will Adaptive Biotechnologies (ADPT) present at the William Blair 46th Annual Growth Stock Conference?

Adaptive Biotechnologies will present on Wednesday, June 3 at 3:20 p.m. Central Time. According to Adaptive Biotechnologies, a live and archived webcast of this presentation will be accessible via the Investors section of its website for interested parties.

Is there a webcast for Adaptive Biotechnologies’ ADPT presentation at the William Blair Growth Stock Conference?

Yes, Adaptive Biotechnologies will provide a live and archived webcast of its William Blair conference presentation. According to Adaptive Biotechnologies, investors can access this webcast through the Investors section of the company’s official website at www.adaptivebiotech.com.

What is Adaptive Biotechnologies’ schedule at the Craig-Hallum 23rd Annual Institutional Investor Conference?

Adaptive Biotechnologies will host 1x1 investor meetings on Thursday, May 28 at the Craig-Hallum conference. According to Adaptive Biotechnologies, these meetings will take place in Minneapolis, Minnesota, giving investors direct access to company management for discussion and questions.

What does Adaptive Biotechnologies (ADPT) focus on in its business?

Adaptive Biotechnologies is a commercial-stage biotechnology company focused on the adaptive immune system. According to Adaptive Biotechnologies, its aim is to translate the genetics of the adaptive immune system into clinical products to diagnose disease and support treatment decisions for patients.

Where can investors find Adaptive Biotechnologies’ ADPT investor presentation from June 3?

Investors can find the June 3 William Blair presentation in the Investors section of Adaptive Biotechnologies’ website. According to Adaptive Biotechnologies, both a live stream and archived webcast will be available at www.adaptivebiotech.com for on-demand viewing.